ArticleJournal of Cancer2021
PD-L1 Expression in Chinese Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Multi-Center Retrospective Observational Study.
Abstract read
In one paragraph
Article in Journal of Cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Consistency analysis of programmed cell death ligand-1/thyroid transcription factor-1 dual staining in malignant pleural effusion and lung adenocarcinoma histology specimens.Journal of thoracic disease · 2026Article
- Comparative effectiveness and safety of systemic therapies for treatment-naïve, PD-L1 expression <1% advanced NSCLC: a systematic review and network meta-analysis.Translational lung cancer research · 2025Article
- A retrospective cross-sectional study of FGFR2b alterations in Chinese patients with advanced squamous non-small cell lung cancer: prevalence, programmed death-ligand 1 co-expression patterns, and association with clinical outcomes.Translational lung cancer research · 2025Article
- Economic Evaluation of Penpulimab Plus Paclitaxel and Carboplatin Combination Therapy as First-Line Treatment for Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer in China.Clinical drug investigation · 2025Article
- The role of EGFR mutations in sensitivity of PD-1/PD-L1 blockade in non-small cell lung cancer.American journal of cancer research · 2025Review
- Senescent immune cells in the tumor microenvironment: emerging insights into cancer immunotherapy resistance.Frontiers in immunology · 2025Review
- Epidemiological, pathological, and molecular characteristics of lung cancer in Casablanca, Morocco: a retrospective study.The Pan African medical journal · 2025Article
- The predictive value of total body PET/CT in high PD-L1 expression and immunotherapy in advanced non-small cell lung cancer patients.Frontiers in oncology · 2025Article
- PD-L1 expression in patients with non-small-cell lung cancer is associated with sex and genetic alterations: A retrospective study within the Caucasian population.Thoracic cancer · 2024Article
- Article
- Immunotherapy for advanced non-small cell lung cancer with negative programmed death-ligand 1 expression: a literature review.Translational lung cancer research · 2024Review
- Association between the modified lung immune predictive index and clinical outcomes of advanced non-small cell lung cancer treated with first-line immune checkpoint inhibitors combined with chemotherapy.Journal of thoracic disease · 2023Article
- The prognostic and predictive roles of plasma C-reactive protein and PD-L1 in non-small cell lung cancer.Cancer medicine · 2023Article
- The Real-world Therapeutic Analysis of First-line Immunotherapy in Chinese Patients with Drive Gene Positive for Advanced Non-Small Cell Lung Cancer.Journal of Cancer · 2023Article
- Role of sex and sex hormones in PD-L1 expression in NSCLC: clinical and therapeutic implications.Frontiers in oncology · 2023Review
- Association between PD-L1 and Ki-67 expression and clinicopathologic features in NSCLC patients.American journal of translational research · 2023Article
- Immune checkpoint inhibitors for non-small cell lung cancer patients on steroid or non-steroidal anti-inflammatory drugs treatment-therapeutic indication or therapeutic efficacy?Translational cancer research · 2022Article
- The predictive value of total-body PET/CT in non-small cell lung cancer for the PD-L1 high expression.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Xin YangKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Pathology, Peking University Cancer Hospital & Institute, Beijing, China.
Lili JiangDepartment of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Yan JinDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
Peng LiDepartment of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Yingyong HouZhongshan Hospital of Fudan University, Shanghai, China.
Jingping YunDepartment of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Chunyan WuDepartment of Pathology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Wenyong SunZhejiang Cancer Hospital, Hangzhou, Zhejiang, China.
Xiangshan FanNanjing Drum Tower Hospital, Nanjing, Jiangsu, China.
Dong KuangDepartment of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Weiya WangDepartment of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Jinsong NiThe first hospital of Jilin University - The Eastern Division, Changchun, Jilin, China.
Anhua MaoMedical Affairs Department, MSD China, Shanghai, China.
Wenmin TangMedical Affairs Department, MSD China, Shanghai, China.
Zhenhua LiuMedical Affairs Department, MSD China, Shanghai, China.
Jiali WangMedical Affairs Department, MSD China, Shanghai, China.
Suijun XiaoMedical Affairs Department, MSD China, Shanghai, China.
Yuan LiDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
Dongmei LinKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Pathology, Peking University Cancer Hospital & Institute, Beijing, China.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
22C3 antibodydriver mutationsimmunohistochemistrynon-small cell lung cancerprogrammed death-ligand 1
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.